Ignite Creation Date:
2024-05-05 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00016692
Status:
TERMINATED
Last Update Posted:
2006-04-27
First Post:
2001-05-24
Brief Title:
Safety and Tolerability of Z-100 in Patients With Early HIV Infection
Sponsor:
Zeria Pharmaceutical
Organization:
Zeria Pharmaceutical
Study Overview
Official Title:
A Phase 1b Multicenter Double-Blind Placebo-Controlled Randomized Study on the Safety and Tolerability of Z-100 in Early HIV-1 Infected Patients
Status:
TERMINATED
Status Verified Date:
2001-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to see if Z-100 an investigational drug treatment is safe in HIV patients who have never received treatment for their HIV who have not been taking highly active antiretroviral therapy HAART for at least 8 weeks or who have been stable on their current first or second HAART regimen for at least 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Zeria Protocol 85D10104 | None | None | None |